NanoMed Pharmaceuticals has announced that founders Russell J. Mumper, Ph.D. and Michael Jay, Ph.D. have been issued U.S. Patent 7,153,525 entitled "Microemulsions As Precursors To Solid Nanoparti
Applied Digital Solutions, though its subsidiary VeriChip Corporation has announced today that the U.S. Patent and Trademark Office has granted VeriChip Corp. a patent for its portable RFID asset
MedImmune issued the following statement regarding today's U.S. Supreme Court decision in MedImmune, Inc. vs. Genentech, Inc. et al.: By granting MedImmune's appeal, the U.S. Supr
Ryogen LLC announced today that the company have entered into a nonexclusive license agreement with Invitrogen Corporation, whereby Invitrogen has licensed from Ryogen the patent directed to the clinic
CogState has announced that it has been issued a patent from the Unites States Patent & Trade Mark Office (US patent no. 7,163,513) for the key technology platform used in its computer-based tests
Acusphere, Inc. announced today the issuance of U.S. Patent No. 7,160,557 B2, entitled "Matrices Formed of Polymer and Hydrophobic Compounds for Use in Drug Delivery." The patent covers the s
Nanion Technologies GmbH, a supplier of automated, parallel patch-clamp systems based in Munich, Germany, has announced that they would appeal the decision of the European Patent Office (EPO) to uphold t
Heska Corporation has announced that it has completed the sale of its rights in a worldwide patent portfolio covering a number of major allergens and the genes that encode them to
Access Pharmaceuticals, Inc has announced that the Company has received a "Notice of Allowance" letter from the United States Patent and Trademark Office for its patent application entitled "Liqu
Nano Chemical Systems announced today that it has filed a US Patent application on a breakthrough new material that exhibits light (luminescent) in the absence of heat. This Nano-enhanced
Date: Monday, 4-Sep-2006
Pfizer has said that a federal court in the Middle District of North Carolina has upheld the company's U.S. patent covering amlodipine besylate, the active ingredient in Norvasc, the world's most-prescribed branded medicine for treating hypertension.The patent had been challenged by the generic manufacturer, Synthon Pharmaceuticals.
Judge James A. Beaty ruled that the patent (U.S. Patent No. 4,879,303) covering amlodipine besylate is valid and infringed by the generic manufacturer's product. The decision, which is subject to appeal, prohibits Synthon from launching a generic version of amlodipine until September 2007.
"The court has affirmed the validity of our Norvasc patent. We will continue to defend against any patent challenges that seek to undermine the incentives established for bringing innovative medicines to patients," said Allen Waxman, Pfizer's general counsel. In January 2006, the same Norvasc patent was held valid and infringed by Apotex in a decision by the Northern District Court of Illinois.
http://www.pfizer.com/